Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Parry, Marina ^a   Rose Zerilli, Matthew J J ^a   Gibson, Jane ^a   Ennis, Sarah ^a   Walewska, Renata ^b   Forster, Jade ^a   Parker, Helen ^a   Davis, Zadie ^b   Gardiner, Anne ^b   Collins, Andrew ^a   Oscier, David G ^a,b   Strefford, Jonathan C ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH2 RECEPTOR; TUMOR PROTEIN;

AMOTL1 GENE; ARTICLE; CBFA2T3 GENE; CLINICAL ARTICLE; COHORT ANALYSIS; COPY NUMBER VARIATION; CREBBP GENE; CUL1 GENE; DNA EXTRACTION; EXOME; EZH2 GENE; FAT4 GENE; FBXO11 GENE; FLNC GENE; GENE DELETION; GENE IDENTIFICATION; HUMAN; MAP3K14 GENE; MLL2 GENE; MUTATIONAL ANALYSIS; MUTATOR GENE; NOTCH2 GENE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PLA2G4D GENE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SPEN GENE; SPLENIC MARGINAL ZONE LYMPHOMA; TNFAIP3 GENE; TRRAP GENE; USH2A GENE; WHOLE EXOME SEQUENCING; CHROMOSOME 7; CLINICAL TRIAL; FEMALE; GENETICS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; METABOLISM; MUTATION; PATHOLOGY; SPLENIC NEOPLASMS;

CHROMOSOMES, HUMAN, PAIR 7; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MUTATION; NEOPLASM PROTEINS; SPLENIC NEOPLASMS;

EID: 84892529734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083244     Document Type: Article

References (26)

1. Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E et al. (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22: 487-495. doi: 10.1038/sj.leu.2405068. PubMed: 18094718.
2. Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J et al. (2010) Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 116: 1479-1488. doi:10.1182/blood-2010-02-267476. PubMed: 20479288.
3. Watkins AJ, Hamoudi RA, Zeng N, Yan Q, Huang Y et al. (2012) An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLOS ONE 7: e44997. doi:10.1371/journal.pone.0044997. PubMed: 23028731.
4. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T et al. (2011) Alteration of BIRC3 and multiple other NF-êB pathway genes in splenic marginal zone lymphoma. Blood 118: 4930-4934. doi:10.1182/blood-2011-06-359166. PubMed: 21881048.
5. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM et al. (2009) The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 113: 4918-4921. doi:10.1182/blood-2008-08-174110. PubMed: 19258598.
6. Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S et al. (2012) Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia 26: 1638-1646. doi:10.1038/leu.2012.3. PubMed: 22222599.
7. Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG et al. (2012) Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 209: 1553-1565. doi:10.1084/jem.20120910. PubMed: 22891276.
8. Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S et al. (2012) The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 209: 1537-1551. doi:10.1084/jem.20120904. PubMed: 22891273.
9. ISCN (2009) An International System for Human Cytogenetic Nomenclature: Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature Shaffer LG, Slovak ML, Campbell LJ, editors. Basel: S.Karger.
10. Matthews C, Catherwood M, Morris TC, Alexander HD (2004) Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols. Leuk Lymphoma 45: 1899-1904. doi:10.1080/10428190410001710812. PubMed: 15223652.
11. Quinlan AR, Hall IM (2010) BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26: 841-842. doi:10.1093/ bioinformatics/btq033. PubMed: 20110278.
12. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD et al. (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22: 568-576. doi: 10.1101/gr.129684.111. PubMed: 22300766.
13. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164. doi:10.1093/nar/gkq603. PubMed: 20601685.
14. Consortium. GP, Durbin RM, Abecasis GR, Altshuler DL, Auton A et al. (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073. doi:10.1038/nature09534. PubMed: 20981092. Available online at: doi:10.1038/nature09534 Available online at: PubMed: 20981092
15. Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Chen X et al. (2011) 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia 25: 489-497. doi:10.1038/leu.2010.288. PubMed: 21151023.
16. Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C et al. (2012) FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 481: 90-93. PubMed: 22113614.
17. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A et al. (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471: 189-195. doi:10.1038/nature09730. PubMed: 21390126.
18. Salaverria I, Akasaka T, Gesk S, Szczepanowski M, Burkhardt B et al. (2012) The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype. Genes Chromosomes Cancer 51: 338-343. doi:10.1002/gcc.21919. PubMed: 22420028.
19. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, et al. (2012) An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 22: 683-697
20. Fresquet V, Robles EF, Parker A, Martinez-Useros J, Mena M et al. (2012) High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. Br J Haematol 158: 712-726. doi:10.1111/j.1365-2141.2012.09226.x. PubMed: 22816737.
21. Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J et al. (2011) Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 17: 1535-1545. doi: 10.1158/1078-0432.CCR-10-2509. PubMed: 21278247.
22. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ et al. (2009) Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest 27: 549-560. doi: 10.1080/07357900802620794. PubMed: 19229700.
23. Kim JH, Jung EJ, Lee HS, Kim MA, Kim WH (2009) Comparative analysis of DNA methylation between primary and metastatic gastric carcinoma. Oncol Rep 21: 1251-1259. PubMed: 19360301.
24. Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M et al. (2006) Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Lett 241: 213-220. doi:10.1016/j.canlet.2005.10.010. PubMed: 16303245.
25. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J et al. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181-185. doi:10.1038/ng.518. PubMed: 20081860.
26. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726. doi:10.1038/ng.621. PubMed: 20601953.